Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo by Semple, Fiona et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human beta-defensin 3 has immunosuppressive activity in vitro
and in vivo
Citation for published version:
Semple, F, Webb, S, Li, H-N, Patel, HB, Perretti, M, Jackson, IJ, Gray, M, Davidson, DJ & Dorin, J 2010,
'Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo' European Journal of
Immunology, vol. 40, no. 4, pp. 1073-1078. DOI: 10.1002/eji.200940041
Digital Object Identifier (DOI):
10.1002/eji.200940041
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
European Journal of Immunology
Publisher Rights Statement:
Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does
not permit commercial exploitation
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Human b-defensin 3 has immunosuppressive activity
in vitro and in vivo
Fiona Semple1, Sheila Webb1, Hsin-Ni Li2, Hetal B. Patel3,
Mauro Perretti3, Ian J. Jackson1, Mohini Gray2, Donald J. Davidson2
and Julia R. Dorin1
1 MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Edinburgh EH4
2XU, Scotland, UK
2 Centre for Inflammation Research, QMRI University of Edinburgh UK
3 William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary
University of London UK
b-defensins are antimicrobial peptides with an essential role in the innate immune
response. In addition b-defensins can also chemoattract cells involved in adaptive
immunity. Until now, based on evidence from dendritic cell stimulation, human b defen-
sin-3 (hBD3) was considered pro-inflammatory. We present evidence here that hBD3 lacks
pro-inflammatory activity in human and mouse primary M/. In addition, in the presence
of LPS, hBD3 and the murine orthologue Defb14 (but not hBD2), effectively inhibit TNF-a
and IL-6 accumulation implying an anti-inflammatory function. hBD3 also inhibits CD40/
IFN-c stimulation of M/ and in vivo, hBD3 significantly reduces the LPS-induced TNF-a
level in serum. Recent work has revealed that hBD3 binds melanocortin receptors but we
provide evidence that these are not involved in hBD3 immunomodulatory activity. This
implies a dual role for hBD3 in antimicrobial activity and resolution of inflammation.
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Introduction
b-defensins are broad spectrum, cationic, antimicrobial peptides.
They are expressed predominantly at mucosal surfaces and believed
to be important components of innate immunity although their
precise in vivo role has not been clarified [1]. Human b-defensins
are a multigene family and the main cluster on chromosome 8p23
has been shown to be copy number variable [2]. Increased copy
number in humans is associated with psoriasis and decreased copy
number with Crohn’s disease, suggesting involvement in these
autoimmune diseases [3, 4]. Human b defensin-3 (hBD3) is one of
the most cationic of the b-defensins with broad spectrum, salt
insensitive, antimicrobial activity [5]. It is highly expressed in
psoriatic skin and the reproductive tract [6, 7]. Defensins have been
considered pro-inflammatory as their expression increases in
response to TLR ligands, TNF-a, IL-1b, IFN-g and PMA, and
following infection or injury [5, 8, 9]. In addition, they have been
shown to chemoattract CD4 T cells and immature dendritic cells
through CCR6, suggesting that they link innate and adaptive
immunity [10]. hBD3 and 4 also chemoattract monocytes and Mf
[8, 11], and hBD3 has been shown to activate monocytes and
myeloid dendritic cells through TLR-1/2 by inducing expression of
co-stimulatory molecules and NF-kB [12]. Recently, human
a-defensins present in neutrophil granules have been shown to
display anti-inflammatory properties [13].
In this paper we show that hBD3 does not induce TNF-a or IL-6 in
Mf and in fact has potent anti-inflammatory effects on both human
and mouse primary Mf. The anti-inflammatory effect was also
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evident in vivo and in the THP-1 human monocytic cell line and
RAW264.7 mouse Mf cell line. hBD3 effectively inhibited the
inflammatory effects of both LPS and CD40 ligand (CD40L). Recently
it has been shown that hBD3 can interact with melanocortin recep-
tors in vitro [14] and a dominant mutation in this gene in dogs and
arctic wolves is causative for black coat colour [15]. Despite mela-
nocortin 1 receptor (MC1R) and melanocortin 3 receptor (MC3R)
being expressed on Mf and having known immunomodulatory
activity, we show here that these receptors do not mediate the novel,
potent anti-inflammatory effect displayed by hBD3.
Results and discussion
hBD3 is anti-inflammatory in vitro
In contrast to the assumed pro-inflammatory effect of hBD3
summarised above, we show here that synthetic hBD3 inhibits
production of TNF-a by the human myelomonocytic cell line
THP-1 in a concentration-dependent manner (Fig. 1A). The effect
was maximal at 2.5mg/mL, and comparable in magnitude to the
cationic antimicrobial peptide LL37, which is a known immuno-
modulatory peptide [16–18]. This same effect was also evident
using human peripheral blood monocyte derived Mf (Fig. 1B).
Treatments did not affect cell viability as MTT assay measurements
were comparable between treated cells and untreated controls.
Addition of hBD3 to the mouse Mf cell line RAW264.7 also
led to inhibition of TNF-a and IL-6 production (Fig. 1C and D). In
our experimental settings hBD3 did not induce TNF-a or IL-6, in
contrast to the recent report that this defensin activates mono-
cytes and myeloid dendritic cells via TLR1/2, up-regulating the
co-stimulatory molecules CD80, CD86 and CD40 [12]. We
observe our anti-inflammatory effect with 5mg/mL (1 mM) of
synthetic hBD3 by directly measuring the attenuation of
pro-inflammatory cytokine production, whereas Funderburg
et al observe their effects on co-stimulatory molecules with 20 mg/
mL of recombinant hBD3 (and do not measure pro-inflammatory
cytokines). We did, however, observe a slight increase in TNF-a
with hBD3 at 10 mg/mL but only in RAW264.7 cells (Fig. 1D), not
primary Mf or THP-1 cells, suggesting that in specific cells at
higher concentrations of hBD3 there may also be a pro-inflam-
matory effect of hBD3.
The anti-inflammatory effect of both hBD3 and the mouse
orthologue Defb14 [19] was observed in mouse primary BM-derived
Mf (BMDM), reducing the TNF-a response to LPS (Fig. 1E). hBD2
was not an effective suppressor of the TNF-a response to LPS in
mouse cells (Fig. 1E), whereas hBD3 was more effective than LL37
in all mouse strains tested (Fig. 1F). hBD2 has only approximately
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Figure 1. hBD3 down-regulates cytokine production in response to the TLR4 agonist LPS in human and mouse Mf. (A) THP-1 monocyte cell line,
(B) human monocyte-derived Mf, (C and D) RAW264.7 mouse Mf cell line and (E) BMDM from CBA mice were exposed to b-defensin or control
peptides at 5mg/mL, in the presence or absence of LPS for 18 h in serum-free media. TNF-a (or IL-6) in the supernatant was measured by ELISA, n5 6
donors for the human primary cells, n5 3 THP-1, n5 3 RAW264.7 and n5 3 mouse BMDM (from three separate mice). Figure shows means7SEM,
significance assessed by two-way ANOVA, po0.001, po0.01 was calculated by comparing LPS plus peptide to LPS alone. (F) TNF-a levels in
supernatant in BMDM from different mouse strains, treated with hBD3 or LL37 at indicated concentrations, with and without LPS for 18 h, n5 3.
Statistical comparisons are between LPS alone versus LPS with peptide in each strain, po0.001, po0.01, po0.05.
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30% amino acid similarity to hBD3, which may explain lack of anti-
inflammatory effects. Conversely, Defb14, which is 64% identical to
hBD3 [20], did demonstrate anti-inflammatory activity.
The anti-endotoxic effects of LL37 have been shown to be partly
due to direct binding of LL37 to LPS [16, 21]. It has previously been
shown that hBD3 does not inhibit endotoxin binding in a Limulus
assay [22] and we confirmed this finding (Supporting Information)
to demonstrate similar endotoxin activity in the presence and
absence of hBD3. However, the Limulus assay is not a direct
measure of LPS-hBD3 binding; so we also investigated hBD3 effects
after LPS stimulation of cells. Figure 2A shows that TNF-a levels
were significantly reduced even when hBD3 was added to Mf 1h
after LPS. This suggests that even if hBD3 binds LPS to some extent,
most of the hBD3 inhibitory effect is occurring downstream of TLR4
activation by LPS.
Further evidence that hBD3 is endowed with general anti-
inflammatory properties is shown in Fig. 2B. Stimulation with
IFN-g and CD40L results in Mf activation and increased TNF-a, but
here we show that hBD3 inhibited this pro-inflammatory cytokine
response in mouse BMDM. This effect was also evident in C3H/HeJ
Mf, which lack functional TLR4, demonstrating that hBD3 is not
simply inhibiting stimulation by endotoxin contamination. The
anti-inflammatory effect was not evident when cells were exposed
to PAM3CSK4 a TLR1/2 agonist (Fig. 2C). This suggests that hBD3
has an effect on signalling molecules that are used by TLR4 and
CD40 but not TLR1/2. This differs from LL-37, which has been
shown to inhibit pro-inflammatory responses via both TLR4 and
TLR1/2. [16]. As TLR4 and TLR1/2 signalling both involve MyD88
it is possible that hBD3 is affecting components of the non-MyD88
pathway (such as TRAM and TRIF) downstream of TLR4.
hBD3 is anti-inflammatory in vivo
Next, we wished to see whether hBD3 could reduce the
accumulation of TNF-a in mice following exposure to LPS. We
injected 16mg/kg LPS into male Balb/c mice with and without
10 mg of hBD3 and measured serum TNF-a levels 1 h later. We
found that the group injected with hBD3 and LPS had
significantly reduced levels of TNF-a compared with mice
receiving LPS alone (Fig. 2D). This result demonstrates that
hBD3 inhibits LPS-stimulated TNF-a production in vivo as well as
in vitro. The extent of inhibition afforded by hBD3 was
comparable to that conferred by 1 mg IL-10, which protects mice
from endotoxic shock [23], so hBD3 may provide similar
protection.
Melanocortin receptors are not involved in hBD3
anti-inflammatory function
hBD3 is a promiscuous ligand which interacts with CCR6 and
another unknown Mf receptor [14, 24]. In addition, Candille
et al elegantly show that overexpressing the dog orthologue of hBD3
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Figure 2. Dissection of hBD3 anti-inflammatory function and in vivo effects of hBD3. (A) The mouse Mf cell line RAW 264.7 was exposed at various
times up to 1 h with LPS before treatment with hBD3, followed by 18 h incubation. The inhibitory effect was still evident at all time points (n5 2,
po0.05). (B) BMDM from different mouse strains were activated with CD40L (5 mg/mL) and IFN-g (5 ng/mL) (CI) with and without hBD3 for 18 h.
TNF-a levels in supernatants were measured. BMDM were prepared from at least three separate mice for each strain. Statistical comparisons are
between agonist alone versus agonist with hBD3 within each strain, po0.01 by two-way ANOVA. (C) TNF-a levels in supernatant in BMDM from
different mouse strains, treated with hBD3 at indicated concentrations, with and without Pam3Csk4 for 18 h, n5 3. (D) Balb/c male mice were
injected i.p. with 16 mg/kg LPS with or without 10 mg hBD3 in 200 mL saline. After 1 h animals were killed and exsanguinated and serum TNF-a
measured. Figure shows means7SEM and comparison between LPS alone (n5 18) and LPS with hBD3 (n5 21) is statistically different p5 0.032 by
unpaired t-test.
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alters hair colour in transgenic mice via binding to murine MC1R
[14]. We tested whether hBD3 might mediate its anti-inflammatory
effect through MC1R or MC3R, as these receptors are expressed in
Mf, and the known ligand a-melanocortin stimulating hormone is
an anti-inflammatory mediator [25]. The absence of either receptor
has also been reported to influence the response to inflammatory
agents [26, 27]. We tested the naturally defective Mc1r mutant
mouse strain (recessive yellow Mc1re) [28] and an Mc3r knockout
mouse [29]. We found no statistically significant difference between
the ability of hBD3 to reduce TNF-a levels following stimulation of
TLR4 or CD40 in BMDM from WT controls or mutant mice (Fig. 3A
and B). This demonstrates that the anti-inflammatory properties of
hBD3 are not mediated by MC1R or MC3R.
hBD3 Anti-inflammatory effect is not mediated by
IL-10 or cAMP
IL-10 is a well-known anti-inflammatory cytokine that inhibits co-
stimulatory molecule expression on Mf and limits the production
of pro-inflammatory cytokines and chemokines [30]. We inves-
tigated the ability of hBD3 to induce IL-10 in BMDM and
established that IL-10 levels were not altered by hBD3 in the
presence or absence of LPS (Fig. 3C), suggesting that the hBD3
anti-inflammatory effect is not mediated by IL-10.
cAMP is an important controller of the innate immune system,
with a wide range of functions including up-regulation of IL-10
and reduction of TNF-a [31]. Using the membrane permeable
cAMP analogue, 8-Bromoadenosine-cAMP (8Br-cAMP), we
examined similarities between cAMP and hBD3 anti-inflamma-
tory activity. TNF-a levels induced by LPS were markedly reduced
by 8Br-cAMP or hBD3 alone, however a combination of 8Br-
cAMP and hBD3 reduced TNF-a levels further. This effect was
evident at low concentrations of hBD3, where hBD3 alone shows
minimal inhibition of TNF-a (Fig. 3D). Similarly induction of
IL-10 by 8Br-cAMP was inhibited by hBD3 (Fig. 3C). These results
suggest that cAMP and hBD3 act through distinct mechanisms.
Concluding remarks
In conclusion, hBD3 is a potent inhibitor of the accumulation of
pro-inflammatory cytokines TNF-a and IL-6, secreted in response
to the TLR4 agonist LPS and following activation with CD40L.
This effect was not due to direct peptide binding of LPS and was
not mediated through the anti-inflammatory receptors MC1R or
MC3R. In support of this finding hBD3 anti-inflammatory action
was independent of cAMP levels and not controlled by an
increase in IL-10. In addition, administration of hBD3 to mice
reduced LPS-induced serum levels of TNF-a, indicating that hBD3
may be important in controlling inflammation and septic shock.
The copy number variation of b-defensins at the 8p23 cluster may
lead to subtle variation in expression levels in the human
population [2]. Up-regulation of hBD3 is critical to antimicrobial
activity in the epithelia; however, the novel hBD3 functions
presented here suggest a role in the resolution of inflammation,
which is necessary to avoid tissue damage by effectors of
antimicrobial action.
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Figure 3. hBD3 anti-inflammatory effect does not act through MC1R or MC3R and has mechanisms distinct from cAMP. BMDM from (A) MC1R
mutant and (B) MC3R mutant were stimulated with LPS alone or LPS in combination with hBD3 or DefB14 (5mg/mL) or (B only) CD40/IFN-g (CI) alone
or in combination with hBD3 as described. After 18 h, concentrations of TNF-a in the supernatants were measured, n5 3. Statistical comparisons
are between LPS alone versus LPS with peptide in each strain, po0.001, po0.01 by two-way ANOVA. BMDM from Balb/c mice were cultured with
LPS (50 ng/mL) in the presence of 8Br-cAMP (100 mM) and decreasing concentrations of hBD3, as shown, for 18 h. Concentrations of (C) IL-10 and
(D) TNF-a in the supernatants were measured by ELISA.
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Materials and methods
Reagents
Ultra pure LPS from E. coli 0111:B4, Pam3CSK4 and IFN-g were
purchased from InvivoGen (San Diego, USA), pertussis toxin,
polymixin B and 8Br-cAMP (B7880) from Sigma Dorset, UK and
QCL-1000s Endpoint Chromogenic LAL Assay from Lonza Group,
Basel, Switzerland. Mouse CD40L was kindly provided by Dr. David
Gray (University of Edinburgh). hBD3 (GIINTLQKYYCRVRGGR-
CAVLSCLPKEEQIGKCSTRGRKCCRRKK) and hBD2 (GIGDPVTCLKS-
GAICHPVFCPRRYKQIGTCGLPGTKCCKKP) were purchased from
Peptides International Louisville, USA and are oxidised so the
disulfide connectivities are of the canonical b-defensin arrangement
[32]. Defb14 (FLPKTLRKFFCRIRGGRCAVLNCLGKEEQIGIRCSNS-
GRKCCRKKK) and LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLR-
NLVPRTES) were synthesized as previously described [20, 33].
Cells and mice
RAW264.7 cells were maintained in DMEM (GIBCO Paisley, UK)
and THP-1 cells in RPMI containing 10% FBS, essential amino
acids and antibiotics. Balb/c, CBA and C57 Black/6 mice were
obtained from Charles River (UK) and Mc1r e/e and Mc3r KO
mutants were bred in-house. C3H/HeJ OlaHsd-Tlr4 mutants and
C3H/HeN controls were obtained from Harlan Laboratories, UK.
Primary Mf were generated from femur BM and grown in DMEM
containing 10% FBS and 20ng/mL M-CSF (R&D Systems,
Abingdon, UK) for 7 days. Cells were seeded at 1.25 105 into
48-well plates and grown without growth factor for 24 h prior to
treatment. Replicate experiments were done with separate Mf
preparations from at least three mice for each experiment.
Human PBMC preparation
Human venous blood was collected according to Lothian
Research Ethics Committee approvals ]08/S1103/38, using
sodium citrate anticoagulant (Phoenix Pharma, Gloucester,
UK), and cells were separated by Dextran sedimentation,
followed by discontinuous, isotonic Percoll gradient centrifuga-
tion as previously described [33]. PBMC were incubated at
4 106/mL in IMDM (PAA Laboratories, Somerset, UK) at 371C,
5% CO2, for 1 h. Non-adherent cells were removed and adherent
monocytes cultured for 6 days in IMDM with 10% autologous
serum to generate monocyte-derived Mf.
Cell treatment and ELISA
Cells were treated with LPS (50ng/mL), Pam3CSK4 (100ng/mL),
CD40L (3mg/mL) IFN-g (5ng/mL), hBD3, Defb14, LL-37, 8Br-
cAMP (at concentrations shown) or combinations of these as
described, in serum free media then incubated at 371C, 5% CO2 for
18h. Supernatants were collected and centrifuged to remove
particulate debris. Levels of TNF-a, IL-6 and IL-10 in the
supernatants were measured using human or mouse DuoSet ELISA
(R&D Systems) according to the manufacturer’s instructions. Cell
viability was measured using TACS
TM
MTT assay (R&D Systems).
LPS delivery in vivo
Balb/c male mice (5–8wk) were injected with 16mg/kg of LPS
(approx. 200mg/mouse) with or without 10 mg of hBD3 in 200 mL
of PBS. After 1 h mice were killed by cervical dislocation,
exsanguinated and serum TNF-a levels measured by ELISA. All
experiments were covered by Project License PPL 60/3787
granted by the Home Office under the Animal Scientific
Procedures Act 1986, and locally approved by the University of
Edinburgh Ethical Review Committee.
Statistical analysis
GraphPad Prism 5 statistical software was used to determine
statistical significance. One or two-way ANOVA with Bonferroni’s
multiple comparison post-tests were performed. Where appro-
priate, statistical significance was determined by an unpaired
t-test using GraphPad software. For all statistical analyses po0.05
was considered significant. Values are expressed as mean7SEM.
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